Company intelligence / Profile preview

Evelo Biosciences

Cambridge, Massachusetts, United Statesstatnews.com ↗

Ownership: Public · EVLO
Employees: ~66
Development stage: Phase 2

Overview

Evelo Biosciences was developing orally delivered medicines targeting the small intestinal axis for inflammatory diseases. The company faced multiple clinical failures, including EDP1815 for atopic dermatitis in February 2023 and EDP2939 for psoriasis in October 2023. By November 2023, the company had run out of cash and filed for dissolution.

Therapeutic areas: OncologyImmunologyDermatologyPulmonology
Modalities: Live biotherapeutic productsbacterial extracellular vesicles (EVs)
Industry: Biotech

Drug pipeline

6 assets

EDP1815

5 more assets in the full pipeline.

Request access →

Financials

Market cap: $1.9K
Total revenue: $0
Enterprise value: $16.7M

Beyond the preview

Go deeper on Evelo Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evelo Biosciences.

Explore the full profile